On March 26, Charles River Laboratories will host a premier Cell & Gene Therapy Summit, bringing together leading experts, biotech executives, innovators, and investors from across the advanced therapies ecosystem...
The MLSC is proud to sponsor this year’s State of Possible Conference that will bring together executives, scientists, innovators, and policymakers in March at the event that unites this community...
Are you a small manufacturing business owner, startup founder, resource provider, or local business dedicated to manufacturing in Greater Boston? Join the Massachusetts Small Business Development Center for a free,...
The 2026 Medtech Impact Symposium examines how the industry can deliver high-quality treatment at a reasonable cost—for anyone and anywhere—while continuing to innovate and thrive. Morning sessions will explore the...
Tufts University, in partnership with LabCentral, invites you to Tufts in Translation: A Faculty Speaker Series — spotlighting early-stage discoveries with strong translational relevance. Li Zeng, PhD A Smart Way...
The MLSC is proud to sponsor this conference that brings together a passionate network of thought leaders whose work focuses on expanding access to STEM careers for all. This year’s...
Join America’s leading rare disease and orphan drug event in Boston! The World Orphan Drug Congress is an award-winning series of conferences and exhibitions that have grown to become the...
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events and provides this content and information as a convenience to visitors to the MLSC website.
Olaris is a precision diagnostics company that is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging their CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, they are able to harness the power of the body’s own communication system to discover and develop their pipeline of myOLARIS precision diagnostics.
